United Therapeutics Reports Record Q2 2025 Revenue of $798.6M, Authorizes $1B Buyback

UNITED THERAPEUTICS Corp

2025-Q2 EPS reported $13.02 revenue$1,593,000,000

Record total revenue of $798.6 million, up 12% year-over-year, driven by Tyvaso DPI growth of 22% to $315 million.
Board authorized up to $1 billion in share repurchases through March 31, 2026.
Phase 3 TETON 2 study of Nebulized Tyvaso in IPF complete; data expected September 2025.
Orenitram posted record quarterly revenue of $123.9 million, up 16% year-over-year.
Net income of $309.5 million, or $6.86 per basic share, up 11%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.